ClinicalTrials.gg
WithdrawnNCT06159309QoL COVID HBOTUpdated Nov 17, 2026

Quality of Life After Hyperbaric Oxygen Therapy in Post-COVID Patients

An observational study in Long COVID, Long COVID-19 Syndrome and Long Covid19, sponsored by Rutger Lalieu. Withdrawn at 6 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Rutger Lalieu · Observational

How we know

Why this study was withdrawn
No funding secured to start study
Updated Nov 17, 2026Now WithdrawnPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands — 6 open to participants now, 6 under way, 3 of them phase 3. Post-Acute COVID-19 Syndrome · Netherlands.

Started
2023
the only one that year
Observational
7 of 15
none open now
Registered
7th of 15
by date
Lead sponsor
1 of 15
Rutger Lalieu

Among the 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands, this one is the only one that started in 2023, is one of 7 observational ones, and was the 7th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

6 of the 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands, or all of them as a file.
02

Study summary

Post-Covid syndrome, also known as long Covid, is a clinical condition in which patients experience long term symptoms after Covid-19 infection. Treatment options for post-Covid are not effective. Therefore, there is an urgent need for a novel therapy. The first study results of HBOT in post-Covid patients are promising. Previous research from Israel has shown improvements in quality of life after HBOT. However, long term results are unknown. Therefore, this study aims to evaluate quality of life at one year after hyperbaric oxygen therapy in post-Covid patients with cognitive symptoms. It is hypothesized that quality of life at one year after HBOT is improved. Furthermore, this study aims to evaluate return to work after HBOT. To our knowledge this was not done before. An observational prospective cohort study will be conducted to answer the research questions. All post-Covid patients who are treated with hyperbaric oxygen therapy in participating centers, will be eligible for inclusion. Questionnaires and medical doctor consultations will be used in order to collect all data.

There are no risks for participants, since only 7 questionnaires are not part of standard clinical care. The burden is approximately 40 minutes extra in total for participants, compared to standard clinical care.

Read the detailed description

The study design is a prospective observational cohort study. Questionnaires and medical doctor consultations will be used in order to collect all data. All patients treated with HBOT have medical doctor consultations at baseline and every 10th session of HBOT (standard clinical care).

At baseline, the following characteristics will be collected: gender, age, BMI, medical history, Covid infection information, vaccination status, work status before Covid infection, previous Covid treatments, hospital and/or intensive care unit admission during Covid infection and smoking status. Furthermore, all patients treated are asked to fill out the SF-36 and EQ-5D questionnaires, a proprietary post-Covid symptoms questionnaire, and a questionnaire regaring work status. These questionnaires are repeated after 20, 40 (50) sessions of HBOT and after 3 and 12 months after the last treatment session.

During the following medical doctor consultations, side effects, changes in medication and interruptions of HBOT will be recorded as well to monitor compliance.

An interim analysis will be performed after 6 months to continue or stop treatments, based on the clinical results (as measured with the Physical Component Score of the SF-36 questionnaire). The minimal clinically important difference (MCID) to warrant early termination of therapy is if \<5% of patients improves 3 points. The upper limit (and reason to continue) is if >50% achieve an MCID of 7 points.

03

Conditions studied

  • Long COVID
  • Long COVID-19 Syndrome
  • Long Covid19
  • Long Covid 19

Keywords

  • registry
  • covid
  • long-covid
  • post-covid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The population will consist of post-Covid patients from the Netherlands, who are treated with hyperbaric oxygen therapy at several different treatment centers. All patients are adults and will receive standard clinical hyperbaric oxygen therapy at these clinics.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Long COVID patients who are reffered for treatment with hyperbaric oxygen therapy
  • Patients are suffering from cognitive symptoms for >3 months after Covid infection

Exclusion criteria

Exclusion Criteria:

  • Patients who are not able to fill in questionnaires and .
  • Patients who can't read or do not understand the Dutch language
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Long Covid patients

    All post-COVID patients that are referred for hyperbaric oxygen (and that are eligible for treatment)

    Other: Hyperbaric oxygen therapy

Interventions

  • OtherHyperbaric oxygen therapy

    HBOT per local protocol, i.e. 40 sessions 2.4 ATA, at the discretion of the hyperbaric physician

06

What researchers measure

Primary outcomes

  1. Quality of life 3 and 12 months

    Is the expected improvement in quality of life in Long COVID patients after treatment with HBOT maintained at 12-months follow-up

    Time frame: 3 and 12 months

Secondary outcomes

  1. Long Covid symptoms

    What symptoms do Long COVID patients who were referred for HBOT suffer from?

    Time frame: 3 and 12 months

  2. Cognitive complaints

    Is there any improvement of symptoms in Long COVID patients with cognitive symptoms during HBOT and after HBOT?

    Time frame: 3 and 12 months

  3. Work

    Do changes in absence at work occur after treatment with HBOT in Long COVID patients with cognitive symptoms?

    Time frame: 3 and 12 months

  4. Risk factors quality of life

    What are risk factors for low health related quality of life in Long COVID patients with cognitive symptoms who are treated with HBOT?

    Time frame: 3 and 12 months

  5. Profile of non-responders versus responders

    What are the differences in baseline characteristics of patients that are non-responders and responders after HBOT?

    Time frame: 3 and 12 months

07

Study locations

6 sites
  • DVK Hogeveen
    Hoogeveen, Drenthe 7909 AK, Netherlands
  • DVK Geldrop
    Geldrop, North Brabant 5664 HB, Netherlands
  • DVK Waalwijk
    Waalwijk, North Brabant 5141 BM, Netherlands
  • HGC Rijswijk
    Rijswijk, South Holland 2288EG, Netherlands
  • DVK Rotterdam
    Rotterdam, South Holland 3081 AA, Netherlands
  • DVK Amersfoort
    Amersfoort, Utrecht 3813 TZ, Netherlands
08

References and documents

Individual participant data

Plan to share: No — The data is retrieved from patient files (after informed consent). Even though the data is pseudonymised, there is too much risk of confidentialty breach.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Feb 2023; primary completion for Dec 2025, 34 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jun 2025 → Dec 2025 and completion Aug 2025 → Feb 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2023
First posted
Dec 6, 2023
StartEst.
Feb 6, 2023
Primary completionEst.
Dec 2025was Jun 2025
CompletionEst.
Feb 2026was Aug 2025
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Withdrawn No funding secured to start study
changed Nov 17, 2026
Sites
4 sites added, 4 sites removed
Show 4 added (4 Netherlands)
  • DVK Geldrop · Geldrop, Netherlands
  • DVK Waalwijk · Waalwijk, Netherlands
  • HGC Rijswijk · Rijswijk, Netherlands
  • DVK Rotterdam · Rotterdam, Netherlands
Show 4 removed
  • DVK Geldrop · Geldrop, Netherlands
  • DVK Waalwijk · Waalwijk, Netherlands
  • HGC Rijswijk · Rijswijk, Netherlands
  • DVK Rotterdam · Rotterdam, Netherlands
Nov 17, 2026
Primary completion
Jun 2025→Dec 2025
Nov 17, 2026
Study completion
Aug 2025→Feb 2026
Nov 17, 2026
Enrollment
200 (estimated)→0 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Active, not recruiting→Withdrawn
    Why stopped No funding secured to start study
    4 sites added, 4 sites removed
    Show 4 added (4 Netherlands)
    • DVK Geldrop · Geldrop, Netherlands
    • DVK Waalwijk · Waalwijk, Netherlands
    • HGC Rijswijk · Rijswijk, Netherlands
    • DVK Rotterdam · Rotterdam, Netherlands
    Show 4 removed
    • DVK Geldrop · Geldrop, Netherlands
    • DVK Waalwijk · Waalwijk, Netherlands
    • HGC Rijswijk · Rijswijk, Netherlands
    • DVK Rotterdam · Rotterdam, Netherlands
    Primary completion Jun 2025→Dec 2025
    Study completion Aug 2025→Feb 2026
    Enrollment 200 (estimated)→0 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06159309
Lead sponsor
Rutger Lalieu
Responsible party
Rutger Lalieu (Principal Investigator, Hyperbaar Geneeskundig Centrum Rijswijk) — Sponsor-investigator
First posted
Dec 6, 2023
Start date
Feb 6, 2023 (estimated)
Primary completion
Dec 2025 (estimated)
Completion
Feb 2026 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion